On November 7, 2018 Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, reported its broad viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) to be held November 7-11 in Washington DC (USA) (Press release, Transgene, NOV 7, 2018, View Source [SID1234530947]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
myvacTM
Transgene presents first preclinical and translational data supporting its novel myvac platform in a poster entitled:
"Viral based vaccine for personalized neoantigen-directed cancer therapies" (#P148)
Transgene has set up a process aimed at developing a Modified Vaccinia Virus Ankara (MVA)-based, individualized immunotherapy product that recognizes and destroys tumors using their own cancer specific genetic fingerprint.
The immunogenicity of the individualized vaccine has been demonstrated in a humanized mice model.
The immune response observed in the mice model partly overlaps with the one observed in humans, suggesting it can be predicted with the use of an advanced artificial intelligence (AI) approach.
___________________
Invir.IOTM
Transgene and BioInvent are presenting two posters that support their collaboration to develop a novel oncolytic virus encoding for an anti-CTLA-4 antibody:
"Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment" (#P615)
"Generation and characterization of a CTLA-4 antibody with improved FcγR-dependent Treg deletion for tumor microenvironment-targeted oncolytic virotherapy of cancer" (#P602)
More details are available in the press release distributed simultaneously and available on www.transgene.fr.
___________________
Pseudocowpox virus (PCPV)
Transgene will also present a poster on PCPV, the most promising therapeutic candidate amongst the poxviridae recently evaluated by the Company, which could be used as either a single agent or in combination with other viral vectors:
"Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy" (#P181)
Intratumoral administration of PCPV induces tumor-specific T cell responses, reduces tumor size and increases survival in both tumor antigen -dependent and -independent mice models.
PCPV encoding for the HPV-16 E7 antigen induces a strong cellular response against this antigen.
Combining two complementary vectors such as MVA and PCPV is an efficient way to improve tumor growth control.
The four posters will be on display Friday, November 9 and Saturday, November 10 in the Poster Hall (Hall E).